| The somatic genomic landscape of glioblastoma CW Brennan, RGW Verhaak, A McKenna, B Campos, H Noushmehr, ... cell 155 (2), 462-477, 2013 | 5373 | 2013 |
| Integrated genomic characterization of endometrial carcinoma DA Levine, ... Nature 497 (7447), 67-73, 2013 | 5344 | 2013 |
| The molecular taxonomy of primary prostate cancer A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ... Cell 163 (4), 1011-1025, 2015 | 2839 | 2015 |
| The evolutionary history of lethal metastatic prostate cancer G Gundem, P Van Loo, B Kremeyer, LB Alexandrov, JMC Tubio, ... Nature 520 (7547), 353-357, 2015 | 1529 | 2015 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 517 | 2018 |
| Evaluation of methods for modeling transcription factor sequence specificity MT Weirauch, A Cote, R Norel, M Annala, Y Zhao, TR Riley, ... Nature biotechnology 31 (2), 126-134, 2013 | 421 | 2013 |
| Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer AW Wyatt, M Annala, R Aggarwal, K Beja, F Feng, J Youngren, A Foye, ... JNCI: Journal of the National Cancer Institute 109 (12), djx118, 2017 | 420 | 2017 |
| Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ... JAMA oncology 2 (12), 1598-1606, 2016 | 385 | 2016 |
| Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 … DJ Khalaf, M Annala, S Taavitsainen, DL Finch, C Oja, J Vergidis, ... The Lancet Oncology 20 (12), 1730-1739, 2019 | 332 | 2019 |
| Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors D Quigley, JJ Alumkal, AW Wyatt, V Kothari, A Foye, P Lloyd, R Aggarwal, ... Cancer discovery 7 (9), 999-1005, 2017 | 282 | 2017 |
| The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma BC Parker, MJ Annala, DE Cogdell, KJ Granberg, Y Sun, P Ji, X Li, ... The Journal of clinical investigation 123 (2), 2013 | 268 | 2013 |
| A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding Q Huang, T Whitington, P Gao, JF Lindberg, Y Yang, J Sun, MR Väisänen, ... Nature genetics 46 (2), 126-135, 2014 | 236 | 2014 |
| Treatment outcomes and tumor loss of heterozygosity in germline DNA repair–deficient prostate cancer M Annala, WJ Struss, EW Warner, K Beja, G Vandekerkhove, A Wong, ... European urology 72 (1), 34-42, 2017 | 235 | 2017 |
| Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ... European urology 75 (4), 667-675, 2019 | 193 | 2019 |
| Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ... Clinical Cancer Research 23 (21), 6487-6497, 2017 | 170 | 2017 |
| Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression L Latonen, E Afyounian, A Jylhä, J Nättinen, U Aapola, M Annala, ... Nature communications 9 (1), 1176, 2018 | 159 | 2018 |
| Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer G Vandekerkhove, JM Lavoie, M Annala, AJ Murtha, N Sundahl, S Walz, ... Nature Communications 12 (1), 184, 2021 | 136 | 2021 |
| Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer C Herberts, M Annala, J Sipola, SWS Ng, XE Chen, A Nurminen, ... Nature 608 (7921), 199-208, 2022 | 131 | 2022 |
| Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours BC Parker, M Engels, M Annala, W Zhang The Journal of pathology 232 (1), 4-15, 2014 | 128 | 2014 |
| Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network KM Holmes, M Annala, CYX Chua, SM Dunlap, Y Liu, N Hugen, ... Proceedings of the National Academy of Sciences 109 (9), 3475-3480, 2012 | 125 | 2012 |